B1SX34 Overzicht aandelen Boston Scientific Corporation ontwikkelt, produceert en verkoopt medische hulpmiddelen voor gebruik in verschillende interventionele medische specialismen wereldwijd. Meer informatie
Beloningen Risicoanalyse Geen risico's gedetecteerd voor B1SX34 uit onze risicocontroles.
Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
Boston Scientific Corporation Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Boston Scientific Historische aandelenkoersen Huidige aandelenkoers US$545.05 52 Week Hoogtepunt US$561.00 52 Week Laag US$269.73 Bèta 0.80 1 maand verandering 4.92% 3 maanden verandering 18.15% 1 Jaar Verandering 102.07% 3 jaar verandering 124.17% 5 jaar verandering n/a Verandering sinds IPO 201.76%
Recent nieuws en updates
Boston Scientific Corporation (NYSE:BSX) has entered into a definitive agreement to acquire Intera Oncology Inc. Nov 26
Boston Scientific Corporation (NYSE:BSX) has entered into a definitive agreement to acquire Intera Oncology Inc. Nov 25
Boston Scientific Corporation Announces Positive Three-Year Primary Endpoint Results from the OPTION Global Clinical Trial of the Watchman FLX Nov 17 BBoston Scientific Corporation (NYSE:BSX) completed the acquisition of Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders. Nov 15
Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Cortex, Inc. from Ajax Health. Nov 06
Boston Scientific Corporation (NYSE:BSX) has entered into a definitive agreement to acquire Cortex EP from Ajax Health. Nov 05 Meer updates bekijken
Boston Scientific Corporation (NYSE:BSX) has entered into a definitive agreement to acquire Intera Oncology Inc. Nov 26
Boston Scientific Corporation (NYSE:BSX) has entered into a definitive agreement to acquire Intera Oncology Inc. Nov 25
Boston Scientific Corporation Announces Positive Three-Year Primary Endpoint Results from the OPTION Global Clinical Trial of the Watchman FLX Nov 17 BBoston Scientific Corporation (NYSE:BSX) completed the acquisition of Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders. Nov 15
Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Cortex, Inc. from Ajax Health. Nov 06
Boston Scientific Corporation (NYSE:BSX) has entered into a definitive agreement to acquire Cortex EP from Ajax Health. Nov 05
Boston Scientific Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year of 2024 Oct 23
Boston Scientific Corporation Launches Next Generation of Cardiac Mapping for the FARAPULSE™ Pulsed Field Ablation System Oct 19
Boston Scientific Corporation to Report Q3, 2024 Results on Oct 23, 2024 Oct 02
Boston Scientific Corporation Receives Japanese Regulatory Approval for the Farapulse™ Pulsed Field Ablation System Sep 27 Boston Scientific Corporation (NYSE:BSX) completed the acquisition of Silk Road Medical, Inc (NasdaqGS:SILK) from a group of shareholders.
Boston Scientific Corporation Elects David Habiger to Board of Directors Jul 31 Boston Scientific Corporation Provides Earnings Guidance for the Third Quarter and Full Year of Fiscal Year 2024
Boston Scientific Corporation to Report Q2, 2024 Results on Jul 24, 2024 Jul 02
Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Silk Road Medical, Inc (NasdaqGS:SILK) for $1.2 billion. Jun 19
Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Silk Road Medical, Inc (NasdaqGS:SILK) for $1.2 billion. Jun 18
Boston Scientific Corporation Appoints Cheryl Pegus to its Board of Directors May 09
Boston Scientific Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2024 Apr 24
Boston Scientific Corporation to Report Q1, 2024 Results on Apr 24, 2024 Apr 02
Boston Scientific Corporation, Annual General Meeting, May 02, 2024 Mar 21
Boston Scientific Corporation Announces Executive Changes, Effective March 1, 2024 Feb 01 Boston Scientific Corporation Provides Earnings Guidance for the First Quarter and Full Year of 2024
BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion. Jan 09
Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) for $3.7 billion. Jan 08
Boston Scientific Corporation to Report Q4, 2023 Results on Jan 31, 2024 Jan 06
Boston Scientific Corporation Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE™ Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation Dec 29
Nelda J. Connors and David J. Roux Not to Stand for Re-Election as Members of the Board of Directors of Boston Scientific Corporation Nov 24
Boston Scientific Corporation (NYSE:BSX) completed the acquisition of Relievant Medsystems, Inc. Nov 18
Boston Scientific Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023 Oct 28
Boston Scientific Corporation Announces Positive 12-Month Results from the Pivotal AGENT IDE Clinical Trial of the AGENT™ Drug-Coated Balloon Oct 26
Boston Scientific Corporation Provides Earnings Guidance for the Full Year 2023 Sep 21
Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Relievant Medsystems, Inc. from Vensana Capital Management, LLC, Ally Bridge Group, LSV Capital Management, LLC, Morgenthaler Venture Partners IX, L.P. managed by Morgenthaler Management Corporation, Canaan VII, L.P. managed by Canaan Management, Inc., Endeavour Medtech Growth II LP managed by Endeavour Vision SA and others for approximately $850 million. Sep 20
Boston Scientific Corporation Announces FDA Approval for the Latest-Generation watchMAN FLX Pro Left Atrial Appendage Closure Device Sep 07
Boston Scientific Corporation to Report Q3, 2023 Results on Oct 26, 2023 Sep 06
Boston Scientific Corporation Announces Positive 12-Month Results from the Pivotal Advanced Clinical Trial of the FARAPULSE™ Pulsed Field Ablation System Aug 28
Boston Scientific Corporation Receives FDA Approval for the POLARx™ Cryoablation System Aug 09
Boston Scientific Corporation (NYSE:BSX) agreed to acquire EV Business and B Braun of Aesculap AG for €47 million. Jul 28
Boston Scientific Corporation to Report Q2, 2023 Results on Jul 27, 2023 Jun 29
Boston Scientific Corporation (NYSE:BSX) completed the acquisition of an additional stake in M.I.TECH Co.,Ltd (KOSDAQ:A179290) from Synergy Innovation Co., Ltd. (KOSDAQ:A048870) Jun 17 Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors May 13
Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors May 12
Boston Scientific Corporation Receives FDA Clearance for LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System Feb 04 Boston Scientific Corporation Provides Earnings Guidance for First Quarter of 2023 and Full Year 2023
Boston Scientific Corporation, Annual General Meeting, May 04, 2023 Feb 01
Boston Scientific Corporation to Report Q4, 2022 Results on Feb 01, 2023 Jan 04
Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million. Dec 01
Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million. Nov 30
Boston Scientific Corporation Announces the First Results from the ACURATE neo2 Post Market Clinical Follow-up (PMCF) Study Nov 28 Boston Scientific Corporation announced that it expects to receive funding from BeWeld Medical Ltd. Nov 01
Boston Scientific Corporation Announces Impairment Results for the Three Months Ended September 30, 2022
Boston Scientific Corporation to Report Q3, 2022 Results on Oct 26, 2022 Oct 04
Boston Scientific Announces Results from the PROTECTED TAVR Clinical Trial Sep 18
Boston Scientific Corporation Receives FDA Approval for Expanded Labeling of WATCHMAN FLX(TM) LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option Sep 07
Boston Scientific Corporation acquired Obsidio, Inc. Aug 16
Nevro and Boston Scientific Corporation Announce the Settlement of Their Ongoing Intellectual Property Litigations Aug 02
Shine Justice Ltd Announces Execution of Settlement Deed in the Matter of Debra Fowkes (Applicant) in the Class Action Brought by Shine Lawyers Against Boston Scientific Corporation and Boston Scientific Pty Ltd Jul 15
Shine Justice Ltd Announces Execution of Settlement Deed in the Matter of Debra Fowkes (Applicant) in the Class Action Brought by Shine Lawyers Against Boston Scientific Corporation and Boston Scientific Pty Ltd Jul 14
Boston Scientific Corporation to Report Q2, 2022 Results on Jul 27, 2022 Jun 30
Boston Scientific Corporation (NYSE:BSX) has entered into a definitive agreement to acquire a 64% stake in M.I.TECH Co.,Ltd (KOSDAQ:A179290) from Synergy Innovation Co., Ltd. (KOSDAQ:A048870) for approximately KRW 290 billion. Jun 17
Boston Scientific Corporation Announces Executive Changes Apr 06
Boston Scientific Corporation to Report Q1, 2022 Results on Apr 27, 2022 Apr 02
Boston Scientific Corporation Announces Late-Breaking Study Results Reinforce Positive Real-World Outcomes with the WATCHMAN FLX™ LAAC Device Mar 01
Boston Scientific Corporation (NYSE:BSX) completed the acquisition of Baylis Medical Company Inc. Feb 16 Boston Scientific Corporation Announces Impairment Results for the Quarter Ended December 31, 2021
Boston Scientific Initiates Trial to Evaluate Industry's First Modular CRM System Dec 03
Boston Scientific Corporation (NYSE:BSX) completed the acquisition of Global Surgical Business from Lumenis Ltd. Sep 02
Boston Scientific Corporation Receives FDA Clearance for EXALT™ Model B Single-Use Bronchoscope Aug 11
Boston Scientific Corporation Announces Late-Breaking Trial Data at TVT Demonstrate Sustained Safety and Performance of WATCHMAN FLX™ Left Atrial Appendage Closure Device Jul 24
Boston Scientific Corporation (NYSE:BSX) agreed to acquire remaining 73% of Farapulse, Inc. for approximately $390 million. Jun 25
Boston Scientific Corporation Provides Earnings Guidance for the Second Quarter and Full Year 2021 Apr 29
Boston Scientific Corporation Receives FDA Approval for TheraSphere Y-90 Glass Microspheres Mar 19 Boston Scientific Corporation Announces Stephen P. MacMillan Will Not Stand for Re-Election At the Annual Meeting Rendement voor aandeelhouders B1SX34 BR Medical Equipment BR Markt 7D 0.1% -3.0% -4.1% 1Y 102.1% 6.6% -11.4%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: B1SX34 overtrof de BR Medical Equipment industrie, die het afgelopen jaar een rendement 6.6 % opleverde.
Rendement versus markt: B1SX34 overtrof de BR markt, die het afgelopen jaar een rendement opleverde van -11.4 %.
Prijsvolatiliteit Is B1SX34's price volatile compared to industry and market? B1SX34 volatility B1SX34 Average Weekly Movement 2.7% Medical Equipment Industry Average Movement 7.0% Market Average Movement 5.0% 10% most volatile stocks in BR Market 9.4% 10% least volatile stocks in BR Market 2.7%
Stabiele aandelenkoers: B1SX34 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 3% ) van B1SX34 is het afgelopen jaar stabiel geweest.
Over het bedrijf Boston Scientific Corporation ontwikkelt, produceert en verkoopt medische hulpmiddelen voor gebruik in verschillende interventionele medische specialiteiten wereldwijd. Het bedrijf opereert via twee segmenten, MedSurg en Cardiovascular. Het bedrijf biedt hulpmiddelen voor het diagnosticeren en behandelen van gastro-intestinale en pulmonale aandoeningen, zoals resolutieklemmen, biliary stent systemen, stents en elektrocauterisatie verbeterde toedieningssystemen, directe visualisatiesystemen, digitale katheters en duodenoscopen voor eenmalig gebruik; hulpmiddelen voor de behandeling van urologische aandoeningen, waaronder ureterale stents, katheters, mandjes, voerdraden, sheaths, ballonnen, digitale flexibele ureteroscopen voor eenmalig gebruik, holmiumlasersystemen, kunstmatige urinesfincters, lasersystemen, vezels en hydrogelsystemen; en apparaten voor de behandeling van neurologische bewegingsstoornissen en de behandeling van chronische pijn, zoals ruggenmergstimulatorsystemen, eigen programmeersoftware, radiofrequentiegeneratoren, indirecte decompressiesystemen, hulpmiddelen voor praktijkoptimalisatie en diepe hersenstimulatiesystemen.
Meer tonen Boston Scientific Corporation Samenvatting Hoe verhouden de winst en inkomsten van Boston Scientific zich tot de beurswaarde? B1SX34 fundamentele statistieken Marktkapitalisatie R$797.18b Inkomsten(TTM ) R$11.02b Inkomsten(TTM ) R$97.76b
72.9x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) B1SX34 resultatenrekening (TTM ) Inkomsten US$15.91b Kosten van inkomsten US$4.97b Brutowinst US$10.94b Overige uitgaven US$9.15b Inkomsten US$1.79b
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) 1.22 Brutomarge 68.74% Nettowinstmarge 11.27% Schuld/Eigen Vermogen Verhouding 51.9%
Hoe presteerde B1SX34 op de lange termijn?
Bekijk historische prestaties en vergelijking
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2024/12/19 21:51 Aandelenkoers aan het einde van de dag 2024/12/19 00:00 Inkomsten 2024/09/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .
Bronnen van analisten Boston Scientific Corporation wordt gevolgd door 70 analisten. 32 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Jasper Hellweg Argus Research Company David Rescott Baird Ishan Majumdar Baptista Research
Toon 67 meer analisten 
